Time Series Methods to Assess the Impact of Regulatory Action: A Study of UK Primary Care and Hospital Data on the Use of Fluoroquinolones.
autoregressive integrated moving average
fluoroquinolones
impact
interrupted time series
regulatory interventions
risk minimisation measures
segmented regression
Journal
Pharmacoepidemiology and drug safety
ISSN: 1099-1557
Titre abrégé: Pharmacoepidemiol Drug Saf
Pays: England
ID NLM: 9208369
Informations de publication
Date de publication:
Oct 2024
Oct 2024
Historique:
revised:
22
07
2024
received:
28
03
2024
accepted:
16
09
2024
medline:
17
10
2024
pubmed:
17
10
2024
entrez:
16
10
2024
Statut:
ppublish
Résumé
To illustrate the interest in using interrupted time series (ITS) methods, this study evaluated the impact of the UK MHRA's March 2019 Risk Minimisation Measures (RMM) on fluoroquinolone usage. Monthly and quarterly fluoroquinolone use incidence rates from 2012 to 2022 were analysed across hospital care (Barts Health NHS Trust), primary care (Clinical Practice Research Datalink (CPRD) Aurum and CPRD GOLD), and linked records from both settings (East Scotland). Rates were stratified by age (19-59 and ≥ 60 years old). Seasonality-adjusted segmented regression and ARIMA models were employed to model quarterly and monthly rates, respectively. Post-RMM, with segmented regression, both age groups in Barts Health experienced nearly complete reductions (> 99%); CPRD Aurum saw 20.19% (19-59) and 19.29% ( Both segmented regression and ARIMA confirmed the reduction of fluoroquinolones use after RMM across four different UK primary care and hospital databases. Model diagnostics showed good performance in eliminating residual autocorrelation for both methods. However, diagnostics for hospital databases with low incident use revealed the presence of heteroscedasticity and non-normal white noise using both methods.
Substances chimiques
Fluoroquinolones
0
Anti-Bacterial Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e70022Subventions
Organisme : Medicines and Healthcare Products Regulatory Agency
Organisme : NIHR Oxford Biomedical Research Centre
ID : SRF-2018-11-ST2-004
Organisme : UKRI Strategic Priority Fund (SPF) - Alleviate Pain Data Hub
ID : MR/W014335/1
Informations de copyright
© 2024 The Author(s). Pharmacoepidemiology and Drug Safety published by John Wiley & Sons Ltd.
Références
S. B. Soumerai, D. Starr, and S. R. Majumdar, “How Do You Know Which Health Care Effectiveness Research You Can Trust? A Guide to Study Design for the Perplexed,” Preventing Chronic Disease 12 (2015): E101.
J. L. Bernal, S. Cummins, and A. Gasparrini, “Interrupted Time Series Regression for the Evaluation of Public Health Interventions: A Tutorial,” International Journal of Epidemiology 46, no. 1 (2017): 348–355.
European Medicines Agency, “Guideline on Good Pharmacovigilance Practices (GVP) Module V – Risk Management Systems (Rev 2),” (2017), https://www.ema.europa.eu/en/documents/scientific‐guideline/guideline‐good‐pharmacovigilance‐practices‐module‐v‐risk‐management‐systems‐rev‐2_en.pdf.
E. Kontopantelis, T. Doran, D. A. Springate, I. Buchan, and D. Reeves, “Regression Based Quasi‐Experimental Approach When Randomisation Is Not an Option: Interrupted Time Series Analysis,” British Medical Journal 350 (2015): h2750.
A. G. O'Keeffe, S. Geneletti, G. Baio, L. D. Sharples, I. Nazareth, and I. Petersen, “Regression Discontinuity Designs: An Approach to the Evaluation of Treatment Efficacy in Primary Care Using Observational Data,” British Medical Journal 349 (2014): g5293.
L. Li, M. S. Cuerden, B. Liu, S. Shariff, A. K. Jain, and M. Mazumdar, “Three Statistical Approaches for Assessment of Intervention Effects: A Primer for Practitioners,” Risk Management and Healthcare Policy 14 (2021): 757–770.
A. L. Schaffer, T. A. Dobbins, and S.‐A. Pearson, “Interrupted Time Series Analysis Using Autoregressive Integrated Moving Average (ARIMA) Models: A Guide for Evaluating Large‐Scale Health Interventions,” BMC Medical Research Methodology 21, no. 1 (2021): 58.
U.S. Food and Drug Administration, “FDA Reinforces Safety Information About Serious Low Blood Sugar Levels and Mental Health Side Effects With Fluoroquinolone Antibiotics,” (2018), https://www.fda.gov/drugs/drug‐safety‐and‐availability/fda‐reinforces‐safety‐information‐about‐serious‐low‐blood‐sugar‐levels‐and‐mental‐health‐side.
European Medicines Agency, “Quinolone‐ and Fluoroquinolone‐Containing Medicinal Products,” (2019), https://www.ema.europa.eu/en/medicines/human/referrals/quinolone‐fluoroquinolone‐containing‐medicinal‐products.
U.S. Food and Drug Administration, Joint Meeting of the Antimicrobial Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee (Silver Spring, Maryland: FDA, 2015).
Medicines and A. Healthcare Products Regulatory, “Fluoroquinolone Antibiotics: New Restrictions and Precautions for Use due to Very Rare Reports of Disabling and Potentially Long‐Lasting or Irreversible Side Effects,” (2019), https://www.gov.uk/drug‐safety‐update/fluoroquinolone‐antibiotics‐new‐restrictions‐and‐precautions‐for‐use‐due‐to‐very‐rare‐reports‐of‐disabling‐and‐potentially‐long‐lasting‐or‐irreversible‐side‐effects.
N. F. Ly, C. Flach, T. S. Lysen, et al., “Impact of European Union Label Changes for Fluoroquinolone‐Containing Medicinal Products for Systemic and Inhalation Use: Post‐Referral Prescribing Trends,” Drug Safety 46, no. 4 (2023): 405–416.
Medicines and Healthcare products Regulatory Agency, “Fluoroquinolone Antibiotics: Must Now Only be Prescribed When Other Commonly Recommended Antibiotics are Inappropriate,” (2019), https://www.gov.uk/drug‐safety‐update/fluoroquinolone‐antibiotics‐must‐now‐only‐be‐prescribed‐when‐other‐commonly‐recommended‐antibiotics‐are‐inappropriate.
S. Hawley, M. S. Ali, K. Berencsi, A. Judge, and D. Prieto‐Alhambra, “Sample Size and Power Considerations for Ordinary Least Squares Interrupted Time Series Analysis: A Simulation Study,” Clinical Epidemiology 11, no. null (2019): 197–205.
R. J. Hyndman and G. Athanasopoulos, Forecasting: Principles and Practice, 3rd ed. (Melbourne: OTexts, 2021).
R. Jandoc, A. M. Burden, M. Mamdani, L. E. Lévesque, and S. M. Cadarette, “Interrupted Time Series Analysis in Drug Utilization Research Is Increasing: Systematic Review and Recommendations,” Journal of Clinical Epidemiology 68, no. 8 (2015): 950–956.
Medicines and Healthcare products Regulatory Agency, “Fluoroquinolone Antibiotics: Reminder of the Risk of Disabling and Potentially Long‐Lasting or Irreversible Side Effects,” (2019), https://www.gov.uk/drug‐safety‐update/fluoroquinolone‐antibiotics‐reminder‐of‐the‐risk‐of‐disabling‐and‐potentially‐long‐lasting‐or‐irreversible‐side‐effects.
R. Stahlmann and H. Lode, “Safety Considerations of Fluoroquinolones in the Elderly: An Update,” Drugs & Aging 27, no. 3 (2010): 193–209.
D. T. Campbell and J. C. Stanley, Experimental and Quasi‐Experimental Designs for Research (Boston, MA: Houghton Mifflin, 1963).